The CSL Ltd (ASX: CSL) share price is in focus today after the company delivered a 90-day interim CEO review and financial update, revealing revised, lower FY26 earnings guidance and plans for around $5 billion in additional asset impairments.
Image source: Getty Images
What did CSL report?
- FY26 revenue expected to be around $15.2 billion (constant currency).
- FY26 NPATA (excluding restructuring costs and impairments) forecast at approximately $3.1 billion.
- Additional non-cash, pre-tax asset impairments of around $5 billion expected across FY26 and FY27, mostly relating to CSL Vifor intangibles and under-used assets.
- US Immunoglobulin revenue to take a $300 million impact due to inventory normalisation.
- Albumin in China revenue down by $200 million from market value decline, despite increases in volume and market share.
- Other headwinds, including Middle East conflict and product competition, expected to weigh by about $150 million.
What else do investors need to know?
CSL says its core business in plasma collection and influenza vaccines remains strong, with ongoing demand growth in key markets. The transformation and efficiency program continues, targeting $500–$550 million in annual savings by FY28 as the business works to simplify operations and focus capital on value-adding growth.
While US Immunoglobulin and Albumin product segments are both seeing stable or rising demand, short-term revenue has been impacted by price pressure and changes in market dynamics. CSL Seqirus is tracking moderately ahead of earlier forecasts for the year.
Leadership changes are also underway, with a global search for a permanent CEO progressing and commercial leadership transitioning to Diego Sacristan from 1 July 2026.
What did CSL management say?
Interim Chief Executive Officer and Managing Director Gordon Naylor said:
Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise. As a result, we have now revised down our 2026 financial year guidance. CSL's culture and people continue to be first class, the industry is stable and growing and the company has evident strengths in plasma collections and influenza vaccines. I am confident that the company can be returned to profitable growth and my work is to position the business and the next CEO for success.
What's next for CSL?
CSL expects to see revenue growth in its CSL Behring division in the second half of FY26, underpinned by commercial execution and its cost transformation initiatives. Seqirus is also anticipated to outperform previous forecasts.
Management is focused on driving sustainable value through portfolio growth, operational efficiencies, and disciplined capital allocation. The company is streamlining the organisation and accelerating its transformation program. A further update will be provided with CSL's full-year results in August 2026.
CSL share price snapshot
Over the past 12 months, CSL shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which had risen 6% over the same period.
